Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

Clinical trial NCT05147090 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05147090
Sponsor: The University of Hong Kong
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Chronic Hepatitis b NAFLD Cirrhosis Fibrosis, Liver Empagliflozin SGLT2 Inhibitors

Start date: 2022-01-02
Primary completion: 2027-12-31
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.